Freedom Capital Markets analyst Lynne Collier has initiated coverage on Cava Group with a Hold rating and a price target of $95. The rating provides a benchmark for investors evaluating the stock's future performance relative to the set target.

Coverage Details

The initiation by Freedom Capital Markets marks the beginning of formal analysis and reporting on Cava Group. The Hold rating suggests that the stock is expected to perform in line with the market or the analyst's expectations, warranting no immediate buy or sell action.

Key Metrics

Jim Cramer endorsed Cava Group, Inc. (NYSE: CAVA) on CNBC's "Mad Money Lightning Round," calling it the best of the new concepts. "I think there's something there for everybody. There really is. It's tasty, clean, fun," Cramer stated. Supporting this view, UBS analyst Dennis Geiger upgraded Cava Group from Neutral to Buy and raised the price target from $85 to $90 on June 10.

Rating and Target Changes

Cramer also discussed ImmunityBio, Inc. (NASDAQ: IBRX), suggesting it serve as a speculative position. "Let Immunitybio be your speculation," he advised, referencing his book "How to Make Money in Any Market." ImmunityBio presented Phase 3 study data for advanced non-small cell lung cancer at the American Society of Clinical Oncology Annual Meeting on June 1.

Regarding Trulieve Cannabis Corp. (NYSE: TRLV), Cramer described it as a "terrific spec." Trulieve became the first American marijuana company to list on a major U.S. stock exchange, with shares beginning trading on the NYSE under the symbol TRLV on June 10. The host recommended holding Ashland Inc. (NYSE: ASH), which UBS analyst Joshua Spector maintained with a Buy rating and a raised price target of $72 from $66 on June 10.

CAVA shares fell 2.5% to settle at $87.30 on Tuesday. Immunitybio shares fell 5.8% to close at $6.72. Trulieve Cannabis shares dipped 4.7% to close at $9.40, while Ashland shares declined 1.3% to settle at $64.56.